drugset / Trial / NCT03148457

Early Versus Late Initiation of Direct Oral Anticoagulants in Post-ischaemic Stroke Patients With Atrial fibrillatioN (ELAN): an International, Multicentre, Randomised-controlled, Two-arm, Assessor-blinded Trial

NCT03148457 ↗

RandomizedParallel-groupSingle-blindTreatment

Summary

When to start anticoagulation in patients with an acute ischaemic stroke and atrial fibrillation (AF) is a relevant unanswered question in clinical practice. Direct oral anticoagulants (DOACs) are highly effective for secondary stroke prevention in these patients, but DOACs were never initiated \<7 days after stroke onset in recent trials. The ELAN trial will determine the net benefit of early versus late initiation of DOACs in patients with acute ischaemic stroke related to AF. The main objective is to estimate the net benefit of early versus late initiation of DOACs in patients with acute ischaemic stroke related to AF. The secondary objectives are to assess all vascular events and all-cause mortality after early initiation of DOACs in patients with acute ischaemic stroke related to AF compared to late initiation.

Timeline

Start
2017-11-06
Primary completion
2022-12-21
Completion
2023-05-24

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Apixaban Small molecule — —
Subject Dabigatran Unknown — —
Subject Edoxaban Small molecule — —
Subject Rivaroxaban Other / unclassified — —

Indications